Gloria David, Ph.D.

Principal Research Scientist

Gloria David

Gloria David, Ph.D.

Principal Research Scientist

Dr. David currently serves as a Lead Scientist for the Asthma and Allergic Diseases Group for the NIAID Division of Allergy, Immunology, and Transplantation: Statistical and Clinical Coordinating Center (2015-2022).

She is responsible for the scientific and technical oversight of the performance of the coordinating center’s work, which includes clinical operations, data management, as well as statistical, technical, regulatory and administrative support of research in asthma and allergy indications. She works directly with the NIAID Project Office and investigators at clinical sites to define project needs and is responsible for building Rho cross-functional teams to meet those needs, as well as coordinating all activities to ensure the successful completion of these projects. She also provides oversight for subcontractor/vendor activities (e.g., safety labs, sample analysis, and repository sample storage).

Dr. David also has served as co-PI of the Statistical and Clinical Coordinating Center (SACCC) for the NIAID-funded Inner-City Asthma Consortium (ICAC; 2004-2015) and as PI of the NIAID-funded Atopic Dermatitis Vaccinia Network (ADVN; 2008-2011) and the Atopic Dermatitis Research Network (ADRN; 2010-2015) Coordinating Centers.

Through her work on these projects, she has amassed a broad level of expertise providing scientific leadership for observational, interventional, and mechanistic studies.

Prior to joining Rho, Dr. David completed her postdoctoral fellowship at the National Institute of Environmental Health Sciences (2000-2004). Her research focused on genetic and environmental susceptibility to lung cancer and asthma.

Dr. David received her PhD in Pharmacology and Molecular Sciences from the Johns Hopkins University School of Medicine, her Master of Health Sciences in Clinical Research from Duke University School of Medicine, and her BS in Biochemistry from the Pennsylvania State University.

Why Respiratory?

“Asthma and chronic obstructive pulmonary disease (COPD) are significant public health burdens. Currently more than 25 million people in the United States have asthma, and approximately 14.8 million adults have been diagnosed with COPD. My research interest has focused on understanding the genetic and environmental factors that contribute to susceptibility to respiratory diseases. Understanding gene-environment interactions is critical to developing effective prevention and treatment strategies for chronic respiratory diseases, such as asthma and COPD.”

This is what drives Dr. David:

“Having personally witnessed the impact of COPD on a loved one, I am driven by the desire to improve the quality of life for those suffering from chronic lung diseases, such as asthma and COPD, and for their families.”